Tumor Cells evaluation of expressing growth factor as a Potential Prognostic Marker in Ewingâ??s Sarcoma.Marker in Ewingâ??s Sarcoma.
Not Applicable
- Conditions
- Health Condition 1: C402- Malignant neoplasm of long bones of lower limb
- Registration Number
- CTRI/2020/12/030114
- Lead Sponsor
- Roche Products India Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Histological proven, Ewingâ??s sarcoma patients, who were
1.Non-metastatic
2.All ages
3.Both osseous and non osseous
4.Treatment naïve
5.Treated uniformly on EFT 2001 protocol and underwent surgery as local treatment at TMH between 2010-2012 and with a minimum follow up of 6 months
Exclusion Criteria
1. Prior treatment (chemotherapy, radiotherapy or surgery)
2. Metastatic disease at presentation
3. Pathologically inadequate specimens
4. Radiotherapy as definitive local treatment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method